Trials / Completed
CompletedNCT05902962
SAD of IVT VP-001 in PRPF31 Mutation-Associated Retinal Dystrophy Subjects
A Phase 1 Open-Label, Single Arm Dose Escalation Study to Evaluate the Safety and Tolerability of Intravitreally Administered VP-001 in Participants With Confirmed PRPF31 Mutation-Associated Retinal Dystrophy
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 17 (actual)
- Sponsor
- PYC Therapeutics · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
A Phase 1 Open-Label, Single Arm Dose Escalation Study to Evaluate the Safety and Tolerability of Intravitreally Administered VP-001 in Participants with Confirmed PRPF31 Mutation-Associated Retinal Dystrophy
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | VP-001 | Phase 1 open-label, single arm dose escalation study of VP-001 in participants with genetically confirmed PRPF31 mutation-associated retinal dystrophy |
Timeline
- Start date
- 2023-04-20
- Primary completion
- 2025-10-08
- Completion
- 2025-10-08
- First posted
- 2023-06-15
- Last updated
- 2026-04-13
Locations
6 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05902962. Inclusion in this directory is not an endorsement.